Hola,
Are you new here?

GrownValve

financed

A prosthetic heart valve for adults and children, made from the patient’s own ti...

A prosthetic heart valve for adults and children, made from the patient’s own tissue, a replacement heart valve that lasts a lifetime Each year 400,000 people are born with heart valve defects worldwide. Moreover, in the western world, 1 in 8 healthy adults will develop a heart valve problem during their lifetime. Current artificial heart valves made from animal... see more

31/03/2025

GrOwnValve GmbH

4M€

Project Budget: 4M€

Project leader

GrOwnValve GmbH No se ha especificado una descripción o un objeto social para esta compañía.

PARTICIPATION DEPralty Sin fecha límite de participación.

Financing granted El organismo HORIZON EUROPE notifico la concesión del proyecto The day 2025-03-31

HORIZON-EIC-2021-ACCELERATOROPEN-01: EIC Accelerator Open 2021 Scope:The EIC Accelerator supports companies (principally start-ups and SMEs) to scale up high impac...

I+D

Cerrada does 3 years

0% 69% 100%

characteristics of the participant

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Private Information

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

GrOwnValve GmbH

2.50M€ | Leader

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Project duration: 33 months Date Start: 2022-06-23
End date: 2025-03-31

Project leader

GrOwnValve GmbH No se ha especificado una descripción o un objeto social para esta compañía.

Project Budget 4M€

participation deadline Sin fecha límite de participación.

Project description Each year 400,000 people are born with heart valve defects worldwide. Moreover, in the western world, 1 in 8 healthy adults will develop a heart valve problem during their lifetime. Current artificial heart valves made from animal or human donor tissue carry a high risk of tissue rejection, degradation and calcification that limit their lifespan to about 10 years, forcing patients to undergo risky cardiac re-surgery. For children, no dedicated valve product exists, thus, paediatric patients can endure 4-5 surgeries between 0-18 years of age as their bodies outgrow each replacement heart valve. At GrOwnValve we have developed a paradigm shift in heart valve technology: the first autologous valve, grown from the patient’s own tissue, crafted using medical imaging and a 3D printing technique. Our valve lasts a lifetime, eliminating tissue rejection and surgical risks associated with repeated surgery (bleeding, infection and death).

Conecta tu I+D

Entra hoy

Forgot your password?

Financing

Companies

CTIs/Universidades

Projects

researchers